Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

31-GEP Test Predicts Metastasis for Cutaneous Melanoma

Publish date:: April 1, 2019

Key clinical point: A meta-analysis of three studies involving the 31-gene expression profile test showed it accurately predicts recurrence-free, distant metastasis-free, and melanoma-specific survival.

Major finding: There was a 2.96 increased risk of recurrent metastases and a 2.88 increased risk for distant metastases for class 2B tumors.

Study details: A meta-analysis of 1,268 patients with class I through class III melanoma.

Disclosures: Dr. Greenhaw reports a pending relationship with Castle Biosciences.

Citation:

Greenhaw BN et al. AAD 19. Session F055, Abstract 11370.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Dermatologic Surgery

Are laser treatments better than steroids for lichen sclerosus?,

Lasers Expunge Mucosal Tattoos,

MMS Linked With Better Survival in Early-Stage Melanoma,

Acoustic pulse boosts laser tattoo removal,

Systematic Review Indicates Cutaneous Laser Therapy May Be Safe During Pregnancy,